For Healthcare Professionals Outside the US
KISQALI is indicated for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)—negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone‑releasing hormone (LHRH) agonist.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

As demonstrated in MONALEESA-21


NEW first-line OS data in
postmenopausal patients



Additional OS data in
premenopausal patients



OS data in postmenopausal
patients with fulvestrant


aBC, advanced breast cancer; CDK, cyclin-dependent kinase; HER2–, human epidermal growth factor receptor 2–negative; HR+, hormone receptor–positive; OS, overall survival.
Reference: Data on file. Novartis Pharma AG; 2021.